A boutique consultancy firms that offers clinical – commercial stage biotechnology and pharmaceutical companies innovative strategies for Global Clinical Development and Operations as well as Global Medical Affairs using cutting edge approaches to facilitate time from preclinical through commercialization. Provides Executive Leadership for start-ups to well established Healthcare investment institutions.

$106B conglomerate represents China’s 3rd largest and only innovative, vertically integrated biopharmaceutical company on the Hong Kong Stock Exchange. Strong emphasis on innovative, first-in-class oncology, neurology, cardiovascular, rare diseases compounds and enhanced drug delivery technology.

Roles:
US Site Head – The CSPC Pharmaceutical Group/Conjupro Biotherapeutics
Global Vice President of Clinical Development & Medical Affairs
Global Head of Business Development

Responsible for the strategic development of the post-launch Clinical Development activities including Phase IV Observational Clinical Trials and the US. Medical Affairs and Clinical Development lead in the alliance management with Shire. Lead for life-cycle management.
- Lead in designing clinical trials and executing the clinical strategy in support of drug development for early and late-stage drug candidates.